Pharmacokinetic modeling and simulation of etodolac following single oral administration in dogs

Abstract Etodolac is a nonsteroidal anti-inflammatory drug with selective cyclooxygenase-2 inhibition to treat pain and inflammation associated with osteoarthritis in humans and dogs. The aim of the study was to investigate the pharmacokinetics of etodolac following single oral administration of 200 mg to 10 healthy beagle dogs. The plasma concentrations of etodolac were detected using liquid chromatography-tandem mass spectrometry. Pharmacokinetic analysis was conducted using the noncompartmental method and modeling approaches. Etodolac was rapidly absorbed (Tmax = 0.85 h, Ka = 1.49 h−1) and slowly eliminated (T1/2 = 39.55 h) following oral administration to the dogs. A two-compartment pharmacokinetic model with first-order absorption and elimination rate constants was successfully explained for the pharmacokinetic aspects of etodolac in dogs. From a Monte Carlo simulation (1000 repetitions), the accumulation index and AUCτ at steady state were predicted as 1.60 [90% confidence intervals (CI), 1.24–2.81] and 408.18 ng·hr/mL [90% CI, 271.26–590.58 ng·hr/mL], respectively. This study will help to enact a more accurate optimal dosing regimen of etodolac in dogs with osteoarthritis, and may be useful in developing a novel formulation of etodolac for human in the future.

• Publication year

  2018

• Venue

  Xenobiotica; the fate of foreign compounds in biological systems

• Publication date

  2018-12-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/00498254.2018.1524185PMID 30216103
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preparation, Characterization and In Vitro / In Vivo Evaluation of Oral Time-Controlled Release Etodolac Pellets

  2017cited by this paper
• Enantioselective analysis of etodolac in human plasma by LC-MS/MS: Application to clinical pharmacokinetics.

  2016cited by this paper
• Pharmacokinetic modeling and Monte Carlo simulation of ondansetron following oral administration in dogs.

  2015cited by this paper
• Canine cytochrome P-450 pharmacogenetics.

  2013cited by this paper
• Effect of food intake on the pharmacokinetics of sarpogrelate and its active metabolite following oral administration to beagle dogs

  2013cited by this paper
• Renal effects of carprofen and etodolac in euvolemic and volume-depleted dogs.

  2012cited by this paper
• Pharmacological modeling and biostatistical analysis of a new drug

  2010influential reference
• Model selection for time-activity curves: the corrected Akaike information criterion and the F-test.

  2009cited by this paper
• Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs.

  2007cited by this paper
• Etodolac-Liquid-Filled Dispersion into Hard Gelatin Capsules: An Approach to Improve Dissolution and Stability of Etodolac Formulation

  2006cited by this paper
• Guidelines for safe and effective use of NSAIDs in dogs.

  2005influential reference
• Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man

  2004cited by this paper
• Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients.

  2003cited by this paper
• Comparison of the upper gastrointestinal effects of etodolac and aspirin in healthy dogs.

  2001cited by this paper
• Etodolac: An overview of a selective COX-2 inhibitor

  1999cited by this paper
• The gastroduodenal effects of buffered aspirin, carprofen, and etodolac in healthy dogs.

  1999cited by this paper
• Efficacy of etodolac for the treatment of osteoarthritis of the hip joints in dogs.

  1999cited by this paper
• Pharmacokinetics of multiparticulate sustained-release diltiazem preparations in dogs.

  1994cited by this paper
• Etodolac Clinical Pharmacokinetics

  1994influential reference
• Individualizing Drug Dosage Regimens: Roles of Population Pharmacokinetic and Dynamic Models, Bayesian Fitting, and Adaptive Control

  1993cited by this paper
• Profile of etodolac: Pharmacokinetic evaluation in special populations

  1989cited by this paper
• Bioavailability studies with etodolac in dogs and man.

  1984cited by this paper
• The metabolic disposition of etodolac in rats, dogs, and man.

  1981cited by this paper

• Etodolac utility in osteoarthritis: drug delivery challenges, topical nanotherapeutic strategies and potential synergies.

  2024cites this paper
• Oral bioavailability and pharmacokinetics of esculetin following intravenous and oral administration in rats

  2021cites this paper
• Comparative pharmacokinetics of meloxicam oil suspension in pigs at different dosages following intramuscular administration.

  2021cites this paper
• Pharmacokinetic analysis of mosapride following intravenous and oral administration in beagle dogs.

  2020cites this paper
• Pharmacokinetic analysis of two different doses of simvastatin following oral administration in dogs.

  2020cites this paper